Artivion (NYSE:AORT) SVP Andrew Green Sells 6,510 Shares

Artivion, Inc. (NYSE:AORT) SVP Andrew Green sold 6,510 shares of Artivion stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $27.27, for a total value of $177,527.70. Following the completion of the sale, the senior vice president directly owned 53,133 shares of the company’s stock, valued at $1,448,936.91. The trade was a 10.91% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Artivion Price Performance

AORT opened at $25.59 on Friday. The stock’s 50-day moving average price is $26.09 and its 200 day moving average price is $29.21. Artivion, Inc. has a 12-month low of $19.16 and a 12-month high of $48.25. The company has a current ratio of 3.47, a quick ratio of 2.51 and a debt-to-equity ratio of 0.82. The firm has a market cap of $1.25 billion, a price-to-earnings ratio of -365.52 and a beta of 1.25.

Artivion (NYSE:AORT) last announced its earnings results on Thursday, August 6th. The company reported $0.13 EPS for the quarter. The company had revenue of $125.76 million during the quarter, compared to analysts’ expectations of $119.99 million. Artivion had a positive return on equity of 6.07% and a negative net margin of 0.67%. As a group, sell-side analysts expect that Artivion, Inc. will post 0.45 earnings per share for the current year.

Hedge Funds Weigh In On Artivion

A number of institutional investors and hedge funds have recently made changes to their positions in AORT. Caitong International Asset Management Co. Ltd acquired a new stake in Artivion in the third quarter valued at approximately $27,000. Rockefeller Capital Management L.P. grew its holdings in Artivion by 150.0% during the 4th quarter. Rockefeller Capital Management L.P. now owns 665 shares of the company’s stock worth $30,000 after acquiring an additional 399 shares in the last quarter. Larson Financial Group LLC grew its holdings in Artivion by 148.5% during the 4th quarter. Larson Financial Group LLC now owns 942 shares of the company’s stock worth $43,000 after acquiring an additional 563 shares in the last quarter. Smartleaf Asset Management LLC increased its position in shares of Artivion by 47.7% in the 2nd quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company’s stock valued at $52,000 after purchasing an additional 538 shares during the last quarter. Finally, Kemnay Advisory Services Inc. purchased a new stake in shares of Artivion in the 4th quarter valued at approximately $79,000. 86.37% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on AORT shares. Canaccord Genuity Group upped their target price on shares of Artivion from $39.00 to $40.00 and gave the stock a “buy” rating in a research note on Tuesday, August 18th. Citizens Jmp decreased their price target on shares of Artivion from $53.00 to $48.00 and set a “market outperform” rating for the company in a research report on Friday, May 8th. Citigroup restated a “market outperform” rating on shares of Artivion in a research note on Tuesday, July 21st. Needham & Company LLC reaffirmed a “buy” rating and set a $44.00 price objective on shares of Artivion in a research report on Monday, July 20th. Finally, Weiss Ratings cut Artivion from a “sell (d+)” rating to a “sell (d-)” rating in a research note on Tuesday, August 11th. Seven research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Artivion presently has a consensus rating of “Moderate Buy” and an average price target of $44.83.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.